Tretinoin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Tretinoin: Rheumatoid nodulosis
One-Sentence Summary
Tretinoin (all-trans retinoic acid) is a retinoid originally used for acne, acute promyelocytic leukemia, acquired keratosis and palmoplantar keratoderma. The TxGNN model predicts it may be effective for rheumatoid nodulosis, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Rheumatoid nodulosis |
| TxGNN Prediction Score | 0.9984 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, tretinoin is a retinoid, its efficacy in acne and acute promyelocytic leukemia is established, and it may mechanistically be applicable to immune-mediated conditions through general retinoid effects on immune cells.
The data compiled for this report notes that retinoic acid has immunomodulatory activity, for example effects on the Th17/Treg balance. However, no specific link to rheumatoid nodulosis is supported by the available data. The relationship between the original indications (skin and blood disorders) and the predicted indication (a nodular complication of rheumatoid arthritis) is not yet characterised.
The other top predictions are mostly inflammatory or skeletal conditions: juvenile idiopathic arthritis and its synonyms, spondyloarthropathy susceptibility, osteoarthritis, rare skeletal dysplasias, and folliculitis decalvans. Several of these are near-synonyms of one another, so their high scores are likely correlated rather than independent confirmations.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for rheumatoid nodulosis.
For the seventh-ranked prediction (osteoarthritis), two publications were retrieved, but neither supports tretinoin use. One concerns PRP injection for knee osteoarthritis, and the other is a case report of adverse events after arsenic trioxide in acute promyelocytic leukemia.
India Market Information
Tretinoin has 20 valid single-ingredient registrations, with no combination products and none cancelled. Approved indication text was not available for any of them. The main examples are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 217369 | Trebor 0.025% Cream | Cream (tube of 20 gm) | Not specified |
| 36675 | CA Retrans Capsule | Capsule (strip of 10) | Not specified |
| 8570 | Atranza Capsule | Capsule (bottle of 100) | Not specified |
| 220862 | Tretiome 20mg Tablet | Tablet | Not specified |
| 184151 | Retino-A 0.05% Cream | Cream (tube of 20 gm) | Not specified |
Products are available in both oral (capsule, tablet) and topical (cream, gel, ointment) forms.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Differentiating agent (retinoid) used in acute promyelocytic leukemia; not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions (typically includes blood counts, liver function and lipids) |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Contraindications (from the knowledge graph, not label text): The knowledge graph links tretinoin to the following conditions as contraindications:
- Liver, kidney, pancreatic and gallbladder disease
- Congestive heart failure
- Diabetes mellitus and diabetic ketoacidosis
- Osteoporosis and postmenopausal osteoporosis
- Crohn disease and inflammatory bowel disease
- Atopic eczema and sunburn
- Adrenocortical insufficiency and Addison disease
- Psychiatric conditions: anxiety, neurotic, dysthymic, psychotic, schizophreniform and schizoaffective disorders
- Mycosis fungoides and related cutaneous T-cell lymphomas
- Drug Interactions: 323 interactions were identified. The major-level ones are:
- Doxycycline
- Tetracycline
- Minocycline
- Vitamin A
Moderate-level interactions include aprepitant, clarithromycin and naltrexone. Levofloxacin is minor.
- Other considerations from the prediction rationale: Systemic tretinoin carries teratogenicity and mucocutaneous toxicity concerns, which are especially relevant for the paediatric predictions (juvenile arthritis). Retinoids are also known to affect skeletal development adversely, which is relevant to the skeletal dysplasia predictions.
Package insert warnings were not available, so please refer to the package insert for the full safety profile.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (0.9984), with no clinical trials or literature for rheumatoid nodulosis (Evidence Level L5). Package insert safety data and mechanism of action data are also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulatory records, which are currently a blocking gap for safety screening
- Detailed mechanism of action data
- Literature and trial searches specific to retinoids in rheumatoid nodulosis and related rheumatoid or juvenile arthritis conditions
- A defined route and formulation, since oral and topical products are both marketed and the required route for the new indication is not yet established
- A risk assessment of the teratogenicity and the knowledge-graph contraindications for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.